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The G protein 3 (GNB3) subunit and HLA are candidate genes predictive of immune response capacity. We therefore
studied the influence of both gene systems on cellular and humoral immunity against hepatitis B virus (HBV) in 79 HBV
booster-vaccinated healthy volunteers and an independent group of 77 probands after HBV basic immunization. Following
booster vaccination, lymphocyte in vitro proliferation after stimulation with HBV surface antigen was 2.5-fold increased in
GNB3 825T (TC  TT) vs CC allele carriers (P  0.01) and was not influenced by HLA-DRB1 or DQB1 alleles. In addition,
anti-HBs antibody titers in both groups were 2-fold increased in TC vs CC and decreased in TT vs CC allele carriers. However,
antibody titers after HBV booster immunization were elevated in HLA-DQB1*0301 carriers (P corrected 0.027). In summary,
the GNB3 825T allele appears as a marker particularly predictive of cellular and HLA-DQB1*0301 of humoral immune(USA)
HBV; HINTRODUCTION
Genetic host factors play a decisive role in the defense
and elimination of viruses such as HBV. In HBV-infected
patients the clinical course shows a great variety in
terms of disease duration and outcome, e.g., acute or
chronic, fulminant, or progression to hepatocellular car-
cinoma. In HBV vaccinees antibody titers vary substan-
tially. Genetic factors responsible for an effective im-
mune response toward HBV surface antigen (HBsAg)
after vaccination should also induce a strong immunity
toward the virus after infection.
Recently, we described the association of enhanced
cellular in vitro immune responses toward microbial re-
call antigens or HBV with the G protein 3 (GNB3) sub-
unit 825T allele (Lindemann et al., 2001). The GNB3 825T
allele leads to the generation of a functionally active
splice variant of G3 referred to as G3-s (Siffert et al.,
1998). Intracellular signal transduction via G proteins is
generally enhanced in cells from 825T allele carriers
expressing this splice variant. Another gene system in-
volved in specific host defense is the highly polymorphic
complex HLA, of which particular alleles were shown to
be associated with the progression of hepatitis B to
chronicity (Ho¨hler et al., 1997) or with the anti-HBs anti-
body level following HBV basic vaccination (Desombere
et al., 1998; Lango¨-Warensjo¨ et al., 1998; Ho¨hler et al.,2451998). HLA molecules present antigen-derived peptides
to specifically activate the corresponding receptor of T
lymphocytes. In summary, heterotrimeric G proteins in-
volving the 3 subunit encoded by the GNB3 gene are
involved in signal transduction of T lymphocytes, i.e., the
effector cells, while HLA molecules are essential struc-
tures of antigen-presenting cells. The potential influence
of GNB3 C825T allele status on humoral immunity
against HBV has not yet been studied, nor was the
relevance of HLA alleles for cellular HBV immunity in-
vestigated systematically. Therefore, we examined the
impact of GNB3 C825T alleles (CC, TC, and TT) as well
as HLA polymorphisms on cellular and humoral HBV
immune response after vaccination comprehensively.
Here, we describe the association of the GNB3 825T
allele with enhanced cellular response after stimulation
with an HBV protein and peptide and of HLA-DQB1*0301
with increased anti-HBs titers following HBV booster
immunization.
RESULTS
GNB3 genotype and HBV immunity
Following HBV booster immunization, the proliferative
response of peripheral blood mononuclear cells (PBMC)
from 79 probands (CC, n  40; TC, n  30; and TT, n 
9) after in vitro stimulation with the purified large HBs
protein (pre-S1-pre-S2-S) is summarized in Fig. 1. Based
on H3-TdR uptake (Fig. 1A) we observed a 2.8-fold in-responses following HBV vaccination. © 2002 Elsevier Science
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crease in TC heterozygotes (P  0.001), whereas in TT
vs CC carriers the increase was 1.8-fold and nonsignifi-
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cant. Combining hetero- and homozygous carriers of the
GNB3 825T allele (TC  TT), values were 2.5-fold higher
than those of CC carriers (P  0.01). A similar pattern
(Fig. 1B) was obvious after the cellular response was
calculated as stimulation index (SI). The response profile
was changed after considering only the values of pro-
bands with positive response (i.e., SI  2.5). Here, the
increase was 2.0-fold in TC vs CC carriers (P  0.03)
and even 2.4-fold in TT vs CC carriers (P  0.01).
The distribution of low and high in vitro responses
toward the HBs antigen in relation to the GNB3 geno-
types became even clearer after classification of the
count per minute (cpm) values obtained into percentiles
(Table 1). CC homozygotes were overrepresented in the
low (cpm increment 25%) responding group compared
to high responders (cpm increment 75%), in which TC
and TT carriers accumulated (P  0.0008; odds ratio
(OR)  16.7). Furthermore, stimulation with a 9-mer HBs
peptide (CTKPTDGNC, Deulofeut et al., 1993), including
an inverse 9-mer peptide as control, showed a trend
toward higher specific PBMC responses in TT carriers
compared to CC and TC carriers (Fig. 2).
In contrast to HBV-specific cellular response data,
the HBs antibody titers in these probands were obvi-
ously not significantly influenced by the GNB3 geno-
type, although TT carriers presented the lowest, CC
carriers an intermediate, and TC heterozygotes the
highest antibody response after HBV booster (Fig. 3A).
Comparing CC  TT vs TC genotype groups, differ-
ences in antibody levels were also nonsignificant. In
addition, classification of low and high antibody re-
sponder status in a similar way as for the cellular
responses revealed no significant trend (Table 2). In-
terestingly, the only humoral nonresponder among
these booster vaccinated probands displayed the
GNB3 CC genotype. In a second and independent
group of healthy probands (n  77) 6 weeks after a
three-dose course of basic immunization against HBV
a similar relationship between GNB3 genotype and
HBs antibody responses was observed. Again, TC
carriers showed the highest antibody level and TT
carriers lower ones than CC carriers (Fig. 3B, Table 3).
Here also the three nonresponders belonged to the
CC genotype.
Neither the cellular nor the humoral response data
were significantly influenced by the gender of the pro-
bands tested; the same holds for the age distribution.
There was, however, a weak (r  0.38) but significant
(P  0.0006) positive association between the HBV-
specific cellular and humoral responses, as given in
Fig. 4.
TABLE 1
Cellular in Vitro Response toward pre-S1-pre-S2-S HBV Protein
after HBV Booster Immunization Classified by Percentiles and GNB3
Genotypes
Percentilea CC TC TT
25 13 2b 5b
50 10 9 0
75 15 4 1
75 2 15 3
a cpm increment values in 79 booster-vaccinated probands for HBV
were classified by percentiles. Thereafter, numbers of CC, TC, and TT
carriers were given separately for each of four percentile groups.
b Comparison of 25 vs 75 percentile: CC vs TC, P  0.0001,
odds ratio (OR) 48.8; CC vs TC TT, P  0.0008, OR 16.7 (Fisher’s
exact test).
FIG. 1. GNB3 CC, TC, and TT genotypes and T cell responses toward
purified pre-S1-pre-S2-S HBV protein. Results given as cpm increment
(A) showed a 2.8-fold increase in cell proliferation comparing TC and
CC probands and a 1.8-fold one comparing TT and CC probands (CC,
n  40; TC, n  30; TT, n  9). Considering stimulation indices (SI)
for all probands (B) data were comparable to those for cpm increment.
Analyzing only positive results (SI  2.5; CC, n  23/40; TC, n 
25/30; TT, n  4/9) cpm increment values were increased 2.0- and
2.4-fold in TC and TT vs CC allele carriers, respectively (C). Data are
given as means  SEM. *P  0.05 for TC vs CC, †P  0.05 for TC 
TT vs CC, and ‡P  0.05 for TT vs CC (Mann–Whitney test).
246 LINDEMANN ET AL.
HLA-DR and DQ alleles and HBV immunity
Among the booster vaccinees presenting HLA-DRB1
and DQB1 allele frequencies of normal controls (Feren-
cik et al., 1997) there was no significant association
between HBV-specific protein- or peptide-induced cellu-
lar response and HLA class II alleles (Table 4). In con-
trast, the levels of HBs antibodies were significantly
associated with DQB1*0301 (P corrected by Bonferroni
correction  0.027). This HLA allele was overrepresented
in probands with HBs antibodies50% (24 of 33) and the
antibody titer was 1.7-fold higher in DQB1*0301 carriers
than in noncarriers. Associations with other HLA-DRB1
and DQB1 alleles were not significant, but a trend toward
decreased antibody levels was obtained in DRB1*0301
carriers. The HLA-DRB1*04, *08, and *11 types known to
be in linkage disequilibrium with DQB1*0301 appeared
more frequent in the high antibody level group.
DISCUSSION
GNB3 825T allele could be defined here as the first
marker highly predictive of enhanced cellular in vitro
HBV immunity. Cellular immune response toward HBV-
infected somatic cells in vivo results, e.g., in the elimina-
tion of infected cells and in a long-lasting control of viral
replication and, therefore, determines the course of HBV
disease (Chisari et al., 1995; Milich, 1997). Vaccinees
with efficient cellular and humoral HBV immunity are
protected from an HBV infection. Different HBV immunity
in GNB3 CC, TC, and TT genotype carriers could result in
various courses of disease after infection and a different
effectiveness of HBV vaccination. Thus, determination of
GNB3 genotypes may be a diagnostic tool in identifying
FIG. 2. GNB3 CC, TC, and TT genotypes and T cell response towards
9-mer HBs and control peptide. In positively reacting TT carriers (SI 
2.5, 3/9) cellular in vitro proliferation toward HBs peptide (A) was
increased compared to the CC and TC groups (8/37 and 8/29, respec-
tively). Reactions toward the control peptide (B) showed no differences
between GNB3 genotypes (CC, n  12; TC, n  8; TT, n  4). Data
are given as means  SEM.
FIG. 3. GNB3 genotypes and anti-HBs antibody levels in 79 probands
1 week after HBV booster immunization (A) and in 77 probands 6 weeks
after a three-dose course of basic immunization (B). In both groups, TC
carriers displayed the highest and TT carriers the lowest antibody
response. Booster group: CC, n  40; TC, n  30; TT, n  9; basic
immunization group: CC, n  37; TC, n  34; TT, n  6. Data are given
as means  SEM. *P  0.02 for TT vs CC genotypes (Mann–Whitney
test).
TABLE 2
Anti-HBs Antibodies after Booster Immunization Classified
by Percentiles and GNB3 Genotypes
Percentilea CC TC TT
25 11 4b 3b
50 10 8 3
75 10 8 2
75 9 10 1
a Antibody titers in 79 booster-vaccinated probands for HBV were
classified by percentiles. Afterward, numbers of CC, TC, and TT carriers
were given separately for each of four percentile groups.
b Comparison of 25 vs 75 percentile: CC vs TC, OR  3.1; CC vs
TT, OR  0.4 (Fisher’s exact test).
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patients or vaccinees at risk for a disadvantageous out-
come or nonprotection against HBV infection after vac-
cination, respectively. According to our in vitro data cel-
lular HBV immunity in vivo is expected to be more vigor-
ous in 825T allele carriers. This could, hypothetically,
lead to a more effective clearance of the virus but, on the
other hand, also to an increased risk of fulminant
courses. This question should now be addressed by
genotyping HBV-infected patients with different disease
outcomes.
The data presented here extend our previous finding
of an enhanced cellular in vitro response toward pre-S1-
pre-S2-S HBV protein in 825T allele carriers by analyzing
a larger cohort of 79 HBV booster-vaccinated probands.
Apart from the HBV protein, in the present study an
immunodominant 9-mer peptide of the HBV S antigen
was investigated. Again, the GNB3 825T allele carriers
on average displayed the strongest cellular immune re-
sponse. This is also in accordance with data on cellular
in vitro responses toward 12 common recall antigens
(Lindemann et al., 2001). Cellular reactions were lowest
in CC (n  27), intermediate in TC (n  22), and highest
in TT (n  14) genotype carriers. Furthermore, concern-
ing other parameters of cellular immunity (lymphocyte
chemotaxis or CD4 T cell counts) TC and TT genotype
carriers exhibited comparable values which were signif-
icantly (P  0.05) higher than those of CC carriers.
As activation of B lymphocytes via antigen receptor
involves an inhibitory G (Gi) protein (Melamed et al.,
1991) we speculated that antibody production could also
be affected by GNB3 genotype. Indeed, this influence
could be confirmed in two independent groups of pro-
bands (n  79 and n  77, respectively). In probands 1
TABLE 3
Anti-HBs Antibodies after Basic Immunization Classified
by Percentiles and GNB3 Genotypes
Percentilea CC TC TT
25 6 7 5b
50 12 8 0
75 9 8 1
75 10 11 0
a Antibody titers in 77 probands following a three-dose course of
basic immunization were classified by percentiles. Numbers of CC, TC,
and TT carriers were given separately for each of four percentile
groups.
b Comparison of 25 vs 75 percentile: CC vs TT, P  0.04, OR 
0.06 (Fisher’s exact test).
FIG. 4. HBV immunity in 79 booster-vaccinated probands. Cellular
immunity is given as lymphocyte proliferation toward pre-S1-pre-S2-S
HBV protein (cpm increment) and humoral immunity as anti-HBs titer
(IU/L). The correlation between cellular and humoral immunity was
significant (r  0.38; P  0.0006). The continuous line represents the
regression line and the dotted one the 95% confidence interval.
TABLE 4
Distribution of HLA-DRB1 and DQB1 Alleles in HBV
Booster-Vaccinated Probands
HLA allele
Cellular response Humoral response
50% 50% 50% 50% percentilea
DRB1*
01 8 9 10 7
15 10 10 14 6
16 3 1 2 2
03 7 6 10 3
04 9 12 9 12
11 10 12 7 15
12 2 1 2 1
1301 5 6 4 7
1302 3 1 3 1
1303/4 1 1 0 2
14 4 3 1 6
07 4 5 6 3
08 2 3 1 4
09 3 0 1 2
10 0 1 0 1
DQB1*
0201 8 5 9 4
020x 2 5 5 2
0301 14 19 9 24b
0302 6 9 8 7
0303 6 1 4 3
0402 2 2 1 3
0501 8 10 10 8
0502 2 1 2 1
0503 5 2 1 6
0601 4 1 4 1
0602 8 9 12 5
0603 5 6 4 7
0604 4 1 4 1
Note. Frequencies of HLA alleles are given as absolute numbers.
a Cellular responses toward pre-S1-pre-S2-S HBV protein and anti-
HBs antibodies were grouped in values 50 and 50 percentile,
respectively.
b The DQB1*0301 allele was present significantly more frequently in
probands with humoral HBV immune response 50 percentile (P
corrected  0.027). HLA-DRB1*03 always represented DRB1*0301,
DRB1*07 in all cases DRB1*0701. The HLA-DRB1*0103 and HLA-
DQB1*0504, 0605, 0606, 0607, 0608, 0304, 0305, and 0401 alleles have
not been observed in our probands; n  1/79 probands not tested.
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week after HBV booster as well as in those 6 weeks after
a three-dose course of HBV vaccination, anti-HBs titers
were increased in TC and decreased in TT compared to
CC allele carriers.
Humoral immunity against HBV is measurable by a
standard ELISA format and has been determined in nu-
merous vaccination studies. In contrast, cellular HBV
immunity has been investigated only rarely. According to
Degrassi et al. (1992) in vitro lymphoproliferation could
only be induced within a limited time window approxi-
mately 1 week after vaccine administration. In another
study Leroux et al. (1994) were able to observe a clear
cellular response as late as 10 months after the third
vaccination. Compared with previously published re-
ports, H3-TdR uptake and SI values following stimulation
with HBV protein were either lower (Deulofeut et al.,
1993; Bo¨cher et al., 1996; Schuenke et al., 1998) or similar
to (Leroux et al., 1994; Min et al., 1996) those in the data
presented here. The sensitivity of the HBV-specific lym-
phocyte transformation test (LTT) established by us is
most likely reached through the use of different antigen
and PBMC concentrations. Proliferative responses to-
ward the HBsAg 9-mer peptide were also described by
Deulofeut et al. (1993) and were comparable to our re-
sults; the ratio between 9-mer peptide- and HBV protein-
induced proliferations was 1/6 in theirs and about 1/10 in
our study. This difference may be due to the different
HBV proteins: While Deulofeut et al. (1993) examined an
HBsAg without pre-S1-pre-S2 sequences as recall anti-
gen, we utilized a protein of the pre-S1-pre-S2-S region
previously described by Bo¨cher et al. (1996).
Another polymorphic system with potential influence
on antigen-specific immunity is the HLA system. So far
no systematic association study on cellular HBV immu-
nity and HLA has been published. In our study with
healthy vaccinees we did not observe a correlation of
HLA-DRB1 or DQB1 alleles and proliferative in vitro re-
sponses toward either the pre-S1-pre-S2-S antigen or the
9-mer HBs peptide. Future investigations in a larger
cohort have to confirm the preliminary findings. In con-
trast to cellular immunity, associations of HLA alleles
and no, poor, and good anti-HBs antibody responses,
respectively, have been described. None of these asso-
ciation studies was done after HBV booster vaccination
but examined the association with antibody titers follow-
ing a three- or four-dose course of basic immunization.
Especially in humoral “nonresponders” representing 5 to
10% of healthy individuals (Zuckerman et al., 1996) HLA-
DR3 and DR7 individuals were enriched (Craven et al.,
1986). Further, HLA-DRB1*1302, DRB1*14, DQB1*02, and
DQB1*0604 were associated with poor or antibody
nonresponse, while DRB1*01, DRB1*11, DRB1*1301,
DRB1*15, DQB1*0301, DQB1*0501, DQB1*0602, and
DQB1*0603 were more frequent in good responders
(McDermott et al., 1997; Caillat-Zucman et al., 1998; De-
sombere et al., 1998; Ho¨hler et al., 1998; Lango¨-Warensjo¨
et al., 1998; Martinetti et al., 2000).
In our study, probands displaying high anti-HBs anti-
body titers (50%) after HBV booster vaccination
showed a significantly increased frequency for the
DQB1*0301 allele. Combining previous studies and our
results, antibody responses after basic and booster vac-
cination were significantly increased in DQB1*0301 al-
lele carriers.
Some groups studied the correlation of cellular and
humoral HBV immunity. Min et al. (1996) described a
weak correlation between T-cell responses to HBsAg
and antibody titers following vaccination with HBsAg,
and Leroux-Rouel et al. (1994) observed a significant
correlation analyzing humoral and cellular immunity di-
chotomously (high vs low responder and proliferation vs
nonproliferation, respectively). No correlation was re-
ported by McDermott et al. (1999), which agrees with
Degrassi et al. (1992), as HBsAg-responsive T and B
cells display different kinetics of recirculation in the pe-
ripheral blood.
Our own results are in accordance with those of Min et
al. (1996) and Leroux-Rouels et al. (1994), as we obtained
a weak but significant correlation (r  0.38, P 
0.0006). This weak positive correlation could be due to
the fact that the strength of cellular and humoral HBV
immunity is also differentially influenced by HLA-DRB1
and DQB1 alleles. Furthermore, GNB3 polymorphism
may not affect the cellular and humoral HBV immunity of
TT allele carriers in the same way. While these probands
displayed the strongest cellular response toward HBV
antigens (analyzing positively reacting probands), anti-
HBs antibody formation was weakest. In contrast, the
comparison of CC vs TC allele carriers yielded similar
results for cellular and humoral HBV immunity. Therefore,
GNB3 polymorphism only in part acts comparably on
HBV-specific proliferation and anti-HBs antibody produc-
tion. While the increased anti-HBs titers in heterozygous
825T allele carriers are in line with their increased cel-
lular immunity against HBV, the reduced titers in homozy-
gous 825T allele carriers despite vigorous cellular immu-
nity are unexpected. Although this could be an artifact
attributable to the low number of TT individuals in Cau-
casian populations, it should be stressed here that con-
sistent observations were made in two independently
established cohorts. Whether the TC genotype is asso-
ciated with both increased cellular and humoral immu-
nity while the TT genotype is predictive only of increased
cellular immunity remains to be investigated in separate
studies.
The mechanism by which enhanced G protein activa-
tion affects cellular HBV immunity is presumably similar
to that observed for other recall antigens. We showed
recently that lymphoproliferation toward common recall
antigens is significantly reduced in cells treated with
pertussis toxin (PTX), which prevents the activation of Gi-
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and Go-type G proteins by G-protein-coupled receptors
(Lindemann et al., 2001). Most likely, the GNB3 polymor-
phism is associated with a modified activation of a Gi
protein, presumably due to an altered coupling of the
T-cell receptor to phospholipase C (Gukovskaya, 1991).
For B lymphocytes, Gi protein involvement in antigen
receptor-mediated signal transduction has been shown
by Melamed et al. (1991). A PTX-sensitive G protein
regulates tyrosine phosphorylation of phospholipase
C-1 by controlling the activity of a protein tyrosine ki-
nase. According to those data, the influence of GNB3
alleles on antibody production may be explained by al-
tered signal transduction via a Gi protein in B lympho-
cytes.
The influence of gender and age on anti-HBs antibody
titers was studied by Marsano et al. (1998) 1 month after
the second dose of HBsAg. In 200 probands they re-
ported a significantly higher antibody titer in female than
in male subjects. In addition, older subjects tended to
have lower titer levels, but the effect was not significant
in their study, with its relatively narrow age range of
18–39 years. We observed a similar trend in our booster-
vaccinated female probands but not in those after basic
immunization. In addition to their study, we found cellular
HBV immunity 1.6-fold, nonsignificantly increased in fe-
male probands. Confirming and extending their data, the
age of probands was significantly correlated with neither
humoral nor cellular HBV immunity.
As GNB3 and HLA genes are located on chromo-
somes 12 and 6, respectively, an association in terms of
immune response should not be expected. However, the
simultaneous appearance of HLA-DRB1 or DQB1 nonre-
sponder alleles and the GNB3 CC genotype may exert an
additive or even synergistic effect on cellular or humoral
HBV nonresponse.
In summary, individual GNB3 and HLA-DQ alleles are
both predictive of HBV immunity and may therefore help
to explain different courses of immunity after HBV vacci-
nation or following infection with HBV. As a conse-
quence, the vaccination scheme could be modified de-
pending on the presence of GNB3 or HLA-DRB1 or DQB1
alleles; for example, a carrier of the CC genotype and
HLA-DRB1*03 could be injected with a vaccine contain-




Healthy medical staff and students from the University
Hospital of Essen (46 female, 33 male, mean age 26
years, range 20–45) were booster-vaccinated against
HBV (Gen H-B-Vax, 10 g of yeast-derived recombinant
HBsAg, Pasteur-Me´rieux MSD, Leimen, Germany) on an
average of 2 years after their last immunization and
heparinized blood and serum were drawn 1 week after
booster shot to perform an HBV-specific LTT and to
determine anti-HBs antibodies. Besides, another group
of healthy medical staff (56 female, 21 male, mean age 28
years, range 17–58) received a basic immunization
against HBV following a standard protocol of three vac-
cinations at 0, 1, and 6–12 months (Engerix-B, 20 g of
yeast-derived recombinant HBsAg, SmithKline Beecham
Pharma, Mu¨nchen, Germany) and anti-HBs antibodies
were examined 6 weeks after their last shot. All pro-
bands were additionally typed for the GNB3 C825T poly-
morphism and the booster-vaccinated ones also for HLA
class II.
DNA genotyping
Genomic DNA was extracted from EDTA–blood with a
proprietary reagent (Qiagen, Hilden, Germany) according
to the manufacturer’s protocol. GNB3 C825T allele status
was determined after PCR amplification and restriction
analysis as described (Siffert et al., 1998). HLA class II
(DRB1 and DQB1) typings were performed with the poly-
merase chain reaction technique using sequence-spe-
cific primers (Olerup et al., 1992, 1993).
Determination of cellular and humoral HBV immunity
Cellular HBV immunity was determined in booster-
vaccinated probands by LTT using 100,000 and 200,000
PBMC per culture. The HBV antigens were a purified
protein of the pre-S1-pre-S2-S region in concentrations
of 0.25, 0.5, and 1.0 g/ml (adw subtype, kindly provided
by Dr. K.-H. Heermann, Go¨ttingen, Germany) and a 9-mer
peptide of the S region (3, 6, 12.5, 25, 50, and 100 ng/ml,
positions 139–146, CTKPTDGNC). As a control, a non-
sense (inverse) 9-mer peptide (also 3–100 ng/mL, CNG-
DTPKTC) was used. In brief, PBMC from heparinized
blood were collected after Ficoll–Paque density gradient
(Amersham Pharmacia Biotech, Uppsala, Sweden) cen-
trifugation and were incubated with the antigen in 200 l
of cell culture medium (RPMI 1640, GIBCO, Life Technol-
ogies, Paisley, UK) with 10% inactivated pooled human
serum per well of microtiter plates (37°C, 5% CO2). After
5 days the cultures were labeled with 1 Ci of [3H]thy-
midine per well (TRA.120, specific activity 5 Ci/mmol,
Amersham Pharmacia Biotech, Little Chalfont, UK) and
were again incubated for 16 h. Then they were harvested
(Mach III Harvester 96, Tomtec, Hamden, U.S.A.) onto
glass fiber filtermates (Wallac, Turku, Finland) and the
incorporated radioactivity was quantified by liquid scin-
tillation counting (1450 Microbeta Trilux, Wallac). For
evaluation, the median of cpm values in triplicate cul-
tures were considered. Increment cpm values were gen-
erated as HBV-specific minus autologous (unstimulated)
proliferation. SI was defined as the quotient of HBV-
specific and autologous median counts. Thereafter, we
chose the maximum cpm increment or SI value of differ-
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ent antigen concentrations and amounts of PBMC for
quantification of HBV-specific cellular reactions.
Humoral HBV immunity was determined by an HBs
antibody ELISA (Enzygnost Anti-HBs II, Dade Behring,
Marburg, Germany) according to the manufacturer’s in-
structions. Concentrations below 5 IU/L were regarded
as negative.
Statistical analysis
The Mann–Whitney test was used to compare lympho-
cyte proliferation in response to HBV antigens and anti-
HBs antibodies between the CC, TC, and TT genotype
groups and between female and male probands. Un-
paired, two-tailed Student’s t test was applied to examine
if the age distribution of probands within the GNB3 ge-
notypes was equivalent. One-way ANOVA was used to
test if the gender distribution was different in the three
genotype groups. In addition, cellular and humoral HBV
immunity was classified by percentiles and a poor re-
sponse (25%) was compared to high response (75%)
in CC vs TC and TT allele carriers using Fisher’s exact
test. The 100% percentile, i.e., the maximum value, was
129,000 cpm increment for pre-S1-pre-S2-S HBV-LTT and
2,700,000 or 126,000 IU/L of anti-HBs (booster or basic
vaccination group, respectively). Fisher’s exact test was
also applied to compare HLA allele distributions in
booster-vaccinated probands and normal Caucasian vol-
unteers (Ferencik et al., 1997). Associations between
cellular and humoral HBV immunity and HLA alleles
were analyzed by Fisher’s exact test. Bonferroni correc-
tion was applied according to Svejgaard et al. (1994) (P
corrected). Differences were regarded statistically signif-
icant at P  0.05.
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